Chase Sun(300026.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Chase Sun
300026.SZ
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves the fields of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases. The company was founded in 1996 and is headquartered in Tianjin, China.
2.788 T
300026.SZMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking96/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.28%D
    • Profit Margin0.51%C
    • Gross Margin57.43%B
  • Growth ScoreD
    • Revenue YoY-18.09%E
    • Net Profit YoY0.86%C
    • Total Assets YoY-5.99%D
    • Net Assets YoY-1.58%D
  • Cash ScoreC
    • Cash Flow Margin3344.89%A
    • OCF YoY-18.09%E
  • Operating ScoreC
    • Turnover0.44C
  • Debt ScoreA
    • Gearing Ratio15.89%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chase Sun Pharmaceuticals released its performance for the first three quarters, with a net profit attributable to the parent company of 80.7629 million yuan, a decrease of 52.03%

    Zhitong·
    SZ
    300026
    -1.50%
    Zhitong·
    SZ
    300026
    -1.50%

    Chase Sun Pharmaceuticals released its performance for the first half of the year, with a net profit attributable to the parent company of 78.63 million yuan, a decrease of 46.95%

    Zhitong·
    SZ
    300026
    -1.50%
    Zhitong·
    SZ
    300026
    -1.50%

    The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also rising

    Zhitong·
    SH
    600572
    -1.64%
    SZ
    300026
    -1.50%
    SZ
    002166
    +1.13%
    Zhitong·
    SH
    600572
    -1.64%
    SZ
    300026
    -1.50%
    SZ
    002166
    +1.13%

    Chase Sun Pharmaceuticals released its first-quarter performance, with a net profit attributable to the parent company of 60.3297 million yuan, an increase of 3.80%

    Zhitong·
    SZ
    300026
    -1.50%
    Zhitong·
    SZ
    300026
    -1.50%

    Hubei Chenmei Traditional Chinese Medicine signed agreements with multiple parties to jointly promote the high-quality development of the entire industrial chain of Dabieshan authentic medicinal materials

    Zhitong·
    SZ
    300026
    -1.50%
    Zhitong·
    SZ
    300026
    -1.50%
    © 2026 Longbridge｜Disclaimer